# Aclaris Therapeutics (ACRS) — Earnings

ACRS · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/acrs/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2025 |
| Period end | Jun 30, 2025 |
| EPS actual | −$0.13 |
| EPS estimate | −$0.13 |
| EPS surprise | +2.18% |
| Revenue surprise | +29.44% |
| Revenue | $1.8M |
| Revenue estimate | $1.4M |
| Reported | Aug 7, 2025 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1557746/000155837025010789/acrs-20250630x10q.htm) |

Aclaris Therapeutics' most recent quarter in the table is Q2 2025, reported August 7, 2025. It posted a loss of $0.13 per share, matching the $0.13 estimate and a 2.18% beat by the source's measure. Revenue was $1.8 million, 29.44% above the $1.4 million estimate. Against Q2 2024, the loss narrowed from $0.15 per share, while revenue fell 35.7% from $2.8 million.

Every quarter in the table was a loss. The annual loss per share was $1.63 in 2021, $1.33 in 2022, $1.27 in 2023 and $1.51 in 2024. The widest quarterly loss was $1.01 in Q4 2024 and the narrowest $0.02 in Q4 2023. Revenue has been uneven, with large quarters of $19.0 million in Q3 2022 and $17.6 million in Q4 2023 among many near $2 million. Aclaris beat EPS estimates in 14 of the 20 quarters, and in six of the last eight.

The table has no quarter after Q2 2025. In earlier years, third-quarter results came between November 2 and November 8, and fourth-quarter results in the last week of February. The next quarter added here will show whether the loss stays near the $0.12 to $0.13 per share of the first half of 2025.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2025 | Aug 7, 2025 | −$0.13 | −$0.13 | 2.18% | $1.4M | $1.8M |
| Q1 2025 | May 8, 2025 | −$0.15 | −$0.12 | 21.16% | $3.0M | $1.5M |
| Q4 2024 | Feb 27, 2025 | −$0.29 | −$1.01 | -252.28% | $2.1M | $9.2M |
| Q3 2024 | Nov 6, 2024 | −$0.01 | −$0.11 | -1829.82% | $1.6M | $4.3M |
| Q2 2024 | Aug 7, 2024 | −$0.20 | −$0.15 | 26.72% | $1.8M | $2.8M |
| Q1 2024 | May 7, 2024 | −$0.29 | −$0.24 | 16.00% | $1.9M | $2.4M |
| Q4 2023 | Feb 27, 2024 | −$0.34 | −$0.02 | 94.19% | $4.7M | $17.6M |
| Q3 2023 | Nov 6, 2023 | −$0.48 | −$0.41 | 14.55% | $1.6M | $9.3M |
| Q2 2023 | Aug 7, 2023 | −$0.45 | −$0.42 | 6.69% | $1.9M | $1.9M |
| Q1 2023 | May 8, 2023 | −$0.44 | −$0.42 | 3.87% | $1.7M | $2.5M |
| Q4 2022 | Feb 23, 2023 | −$0.45 | −$0.41 | 7.93% | $2.0M | $7.8M |
| Q3 2022 | Nov 8, 2022 | −$0.39 | −$0.30 | 23.31% | $1.6M | $19.0M |
| Q2 2022 | Aug 3, 2022 | −$0.36 | −$0.31 | 13.48% | $1.6M | $1.5M |
| Q1 2022 | May 10, 2022 | −$0.39 | −$0.31 | 21.18% | $1.6M | $1.5M |
| Q4 2021 | Feb 24, 2022 | −$0.37 | −$0.37 | -1.37% | $1.8M | $1.5M |
| Q3 2021 | Nov 2, 2021 | −$0.28 | −$0.35 | -24.25% | $1.8M | $1.7M |
| Q2 2021 | Aug 5, 2021 | −$0.28 | −$0.34 | -23.64% | $1.7M | $1.8M |
| Q1 2021 | May 7, 2021 | −$0.30 | −$0.57 | -87.50% | $1.5M | $1.8M |
| Q4 2020 | Feb 25, 2021 | −$0.31 | −$0.30 | 2.44% | $1.4M | $1.6M |
| Q3 2020 | Nov 4, 2020 | −$0.31 | −$0.25 | 20.00% | $1.5M | $1.4M |

## Frequently Asked Questions

### When did Aclaris Therapeutics (ACRS) last report earnings?

Aclaris Therapeutics last reported on Aug 7, 2025, covering fiscal Q2 2025.

### Did ACRS beat earnings estimates?

Yes. Aclaris Therapeutics reported EPS of −$0.13 for Q2 2025 against a −$0.13 estimate — a 2.18% beat.

### How much revenue did ACRS report last quarter?

Aclaris Therapeutics reported $1.8M in revenue for Q2 2025, against a consensus estimate of $1.4M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).